Labcorp (NYSE:LH) EVP Amy Summy Sells 924 Shares

Posted by George Bondi on Aug 7th, 2026

Labcorp Holdings Inc. (NYSE:LH – Get Free Report) EVP Amy Summy sold 924 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the sale, the executive vice president directly owned 6,956 shares of the company’s stock, valued at $2,133,683.44. The trade was a 11.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Labcorp Stock Performance

NYSE:LH opened at $316.93 on Friday. The company has a 50-day moving average of $278.94 and a 200-day moving average of $272.54. The firm has a market cap of $25.99 billion, a price-to-earnings ratio of 26.21, a price-to-earnings-growth ratio of 1.81 and a beta of 0.87. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $317.10.

Labcorp (NYSE:LH – Get Free Report) last released its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same period in the previous year, the firm earned $4.35 EPS. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Analysts forecast that Labcorp Holdings Inc. will post 18.35 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. Labcorp’s dividend payout ratio is currently 23.82%.

Wall Street Analyst Weigh In

LH has been the topic of a number of recent research reports. Truist Financial lifted their target price on Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Robert W. Baird set a $352.00 target price on Labcorp in a report on Friday, July 31st. Morgan Stanley increased their price target on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Piper Sandler upped their price objective on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research note on Tuesday. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Labcorp has a consensus rating of “Moderate Buy” and a consensus price target of $326.82.

Read Our Latest Analysis on Labcorp

Institutional Trading of Labcorp

Several large investors have recently added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Labcorp during the fourth quarter valued at $26,000. Hilton Head Capital Partners LLC purchased a new position in Labcorp during the 4th quarter valued at about $27,000. JPL Wealth Management LLC purchased a new position in Labcorp during the 3rd quarter valued at about $28,000. Eagle Bay Advisors LLC acquired a new position in shares of Labcorp in the 4th quarter valued at about $29,000. Finally, DV Equities LLC acquired a new position in shares of Labcorp in the 4th quarter valued at about $29,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Company Profile

(Get Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.